// App-Quantinova.ai

335 : Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Mark Yarchoan

Principal Investigators

  • Jennifer N. Durham

  • Nicole Gross

  • Soren Charmsaz

  • James M. Leatherman

  • Shu Zhang

  • Aleksandra Popovic

  • Matthew John Weiss

  • Benjamin Philosophe

  • Richard A. Burkhart

  • William Burns

  • Brad Wilt

  • Elizabeth Sugar

  • Elana J. Fertig

  • Dan Laheru

  • Robert A Anders

  • Elizabeth M. Jaffee

  • Won Jin Ho

Medical Centers

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Department of Pathology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Northwell Cancer Institute, Manhasset, NY

  • Johns Hopkins, Baltimore, MD

  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD

  • University of Michigan, Ann Arbor, MI

  • Johns Hopkins University, Baltimore, MD

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  • Johns Hopkins University, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved